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GRN163Lprostate cancer, especially in its androgen-independent form, may result in the
survival of small populations of resistant cells with tumor-initiating potential. These “cancer stem cells” are
believed to be responsible for cancer relapse, and therapeutic strategies targeting these cells are of great
importance. Telomerase is a ribonucleoprotein enzyme responsible for telomere elongation and is activated
in the majority of malignancies, including prostate cancer, but is absent in most normal cells. Putative tumor-
initiating cells have signiﬁcant levels of telomerase, indicating that they are an excellent target for telomerase
inhibition therapy. In this review, we present some evidence for the hypothesis that conventional therapies
(standard chemotherapy and/or radiation therapy) in combination with telomerase inhibitors may result in
effective and more durable responses.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Prostate cancer is the second most common malignancy found in
men and is responsible for the highest rate of morbidity after lung
cancer [1]. In most cases, localized prostate disease can be treated
efﬁciently using surgery and androgen ablation therapy. However, the
outcome for patients with metastatic disease remains poor [2].
Considering the advanced age for the majority of patients, the
chemotherapy regimens have done little to improve median survival,
and the lethality of the disease in patients with metastatic castrate-
resistant disease remains high [3]. The Gleason classiﬁcation of
prostate tumors remains the best predictor for disease outcome, but
more recently new molecular diagnostic techniques such as identiﬁ-
cation of TMPRSS2:ERG fusion transcripts [4,5], Glutathione-S-
transferase P1 (GSTP1) gene promoter hypermethylation [6,7] and
DD3 expression [8] can assist in early detection, prognosis, and
monitoring of prostate cancer. In addition to diagnostics, current
research in the prostate cancer ﬁeld is focused on the establishment of
new targeted therapies for the patients with metastatic disease. It is
generally believed that cancer relapse in patients may be due to a
small population of cells within the tumor mass which are resistant to
conventional therapies.
2. The cancer stem cell hypothesis
The cancer stem cell hypothesis was described more than 150
years ago [9], but the modern revival of this concept arrived with the
studies performed in leukemia, where it was shown that a single cell+1 214 648 8694.
.O. Marian).
ll rights reserved.with the CD34+/CD38− phenotype had the capacity of inducing the
disease in NOD-SCID mice [10]. More recently, cancer stem cells have
been isolated from solid tumors, ﬁrst in breast cancer, then in
neurological malignancies [11,12]. The term “cancer stem cells” is still
very controversial. Nevertheless, the general consensus is that these
cells must have potent tumor initiation, self-renewal and differentia-
tion capacity [13]. The tumor initiation aspect refers to the capacity of
these cells to form tumors in immunocompromised mice using very
small numbers of cells. Self-renewal capacity is tested by serial
transplantation experiments, where re-isolated cancer stem cells can
be transplanted in secondary and tertiary recipients. The differentia-
tion ability of these cells does not refer to multilineage differentiation
but rather to the capacity of the resulting tumors to be a phenocopy of
the original tumor. An important characteristic of cancer stem cells is
their ability to survive various therapies by activating anti-apoptotic
pathways, increasing activity of membrane transporters and high DNA
repair capacity [14,15]. It is important to point out that the deﬁnition
of cancer stem cells does not imply the cell type fromwhich these cells
originated. This is the reasonwhy for the purpose of this reviewwe are
going to use the term tumor-initiating cells. While the origin of tumor-
initiating cells is highly debated, this review will focus on the intrinsic
properties of these cells in prostate cancer, speciﬁcally on telomerase
as both a biomarker and therapeutic target for this type of malignancy.
The study of these populations of cells is very important, not only for
the basic understanding of malignant transformation and pathogen-
esis, but also as a way to investigate and implement new therapies.
3. Isolation of prostate tumor-initiating cells
To some extent, the amount of knowledge about prostate tumor-
initiating cells is still limited compared to that reported in other
Table 1
The percentage of DU145 CD133+ cells is maintained at low levels in culture after initial
FACS isolation in both monolayer and spheroid cultures
Percentage of DU145 CD133+ cells
Days in culture 14 30 33
Monolayera 0.19 0.19 0.18
Spheroidsb 0.21 0.19 0.21
a The sorted CD 133+ cells were cultured in DMEM/199 media with 10% FBS.
b The sorted CD133+ cells were cultured as spheroids in DMEM/F12 media.
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tumors samples available for investigation, and the difﬁculty in
distinguishing between normal and malignant prostate cells based on
surface markers alone. Because prostate tumor-initiating cells are
present in very low numbers within a primary tumor (usually less
than 1%), the use of cancer cell lines provides an efﬁcient alternative to
clinical samples. The caveat is that one needs to validate any scientiﬁc
knowledge derived from prostate cell lines with studies in primary
tumor counterparts. Cell lines are usually grown in culture medium
supplemented with serum and high Ca2+, conditions that generally
permit growth but also encourage differentiation. Some researchers
are strong advocates of xenograft propagation of human tumors, but
the mouse environment is very different from the human prostate
stromal niche, especially when using subcutaneous or renal capsule
inoculations, and some amount of differentiation is unavoidable. An
alternative is the prostate orthotopic xenograft, but these are difﬁcult
to establish, with high rates of mortality. The combinatorial use of
primary samples, xenografts and cell lines will likely provide the tools
for the most rigorous scientiﬁc investigations.
There are several strategies to isolate prostate tumor-initiating
cells. The most popular strategy employs the use of surface markers
that share the same immunological proﬁle with normal prostate stem
cells. One of these surfacemarkers is CD44, an adhesionmoleculewith
multiple functions that appears to be important in tumor dissemina-
tion and metastasis [16–18]. One research group reported an in-depth
study using CD44high cells isolated fromvarious prostate cell lines [19].
These putative tumor-initiating cells were more proliferative, clono-
genic, tumorigenic, and metastatic than the CD44low cells. The CD44
cells also show properties of progenitor cells, such as BrdU label
retention and expression of several “stemness” factors, such as Oct-3/
4, BMI, β-catenin, and SMO. Moreover, while these cells were AR−,
they had the capacity to differentiate into AR+ cells. The authors
recognized that the CD44high population of cells was still very
heterogeneous and tried to further purify the tumor-initiating
component using additional surface markers. In a subsequent study,
it was shown that CD44high/α2β1 integrinhigh populations were more
tumorigenic than CD44low/α2β1 integrinlow populations when
injected in immunocompromised mice and the authors proposed a
tumorigenic hierarchy of prostate cancer cells based on the expression
of these two markers [20].
Based on the similarities betweenmouse prostate and breast stem-
like cells, another study sought todetermine if a population of CD44+/
CD24− cells identiﬁed tumor-initiating cells in the LNCaP prostate
cancer cell line [21]. These cells were present at a very low level in the
population (0.04%), and show increased clonogenic and differentia-
tion capacity. Importantly, very low numbers of CD44+/CD24− cells
were capable of forming tumors in NOD/SCID mice. These cells were
also able to grow as spheroids in attachment-independent conditions
and possessed an invasive gene signature.
Another important stem cell marker is prominin-1 (CD133), a
pentaspan membrane protein with unclear function [22]. Collins et
al. used a CD44/α2β1 integrinhigh/CD133+ phenotype to isolate
tumor-initiating cells from primary prostate biopsies [23]. The cells
isolated with these markers have a high clonogenic and proliferative
capacity, are highly invasive through matrigel and capable of
differentiation.
The percent age of CD133+ cells is low after the initial puriﬁcation
from primary tumor samples. Using the prostate cancer cell line
DU145 we also ﬁnd low numbers of CD133+ cells (Table 1). CD133+
cells isolated from primary tumors or DU145 cells can be placed back
in culture, using both serum-supplemented media and adherent
conditions or chemically deﬁned media and attachment-independent
conditions (spheroids). Regardless of the media and culture condi-
tions used, the percentage of cells expressing CD133 remains very low
(less than 1%), without any apparent enrichment over time in culture.
This indicates that the culture conditions commonly employed in vitrofor the propagation of prostate tumor stem cells do not allow the
enrichment of this rare population of cells. This is in stark contrast
with brain tumor stem cells, where some degree of positive
enrichment is possible when isolated CD133+ cells are placed in
culture [12]. Importantly, the experiments performed in DU145 cells
indicate that the biology of CD133+ cells in primary tumor samples
and cancer cell lines might be similar, and if true, the prostate cancer
cell lines can be used as a valuable source of research material.
A recent study conﬁrmed the signiﬁcance of CD133 as a marker for
both normal and tumor-initiating prostate cells [24]. Within several
androgen receptor positive (AR+) human prostate cancer cell lines,
CD133+ cells were found at low frequency and were able to self-
renew, generate heterogeneous progenies and were capable of an
unlimited proliferation capacity. The authors of this study also
speculated that CD133 may function differently between normal and
cancer prostate cells and that malignant CD133+ cells are originating
from a malignantly transformed intermediate cell. Finally, it was
conﬁrmed that in addition to CD133+, the CD44/α2β1 integrinhigh/
CD133+ population from the DU145 prostate cancer cell line [25] had
high capacity of self-renewal and differentiation as well as strong
proliferative and tumorigenic potential.
Another popular method to identify tumor-initiating cells is the
isolation of the “side population” (SP). The SP cells are isolated based
on the ability of cells to retain Hoechst dye, and in the LAPC-9 prostate
cancer cell line the SP cells were shown to be more tumorigenic than
the corresponding main population [26]. The LAPC-9 SP cells
possessed other stem cell properties such as capacity of differentiation
in vivo, as well as the ability to sustain subsequent transplantation.
Additional information about stem cell surface makers (e.g. CD133,
CD44, and α2β1 integrin) was not provided by this study.
A different strategy adopted to identify tumor-initiating cells is
based on their capacity to form holoclones — tightly packed clones
with speciﬁc morphology that contain self-renewing cells and have
been hypothesized to contain tumor-initiating cells [27]. The other
two types of clones formed by epithelial cells (meroclones and
paraclones) do not have the sustained proliferation capacity required
for tumor initiation. Holoclones derived from the PC3 prostate cancer
cell line were shown to contain stem-like cells that could initiate
serially transplantable tumors [28]. In contrast, meroclones and
paraclones did not proliferate and failed to initiate tumor develop-
ment. Perhaps not surprising, the holoclones had high levels of CD44,
α2β1 integrin and β-catenin expression, whereas meroclones and
paraclones show reduced expression of these stem cell markers.
However, CD133 expression was not reported in this study.
In our experiments, we examined by immunoﬂuorescence imaging
the signature of DU145 prostate cancer cells grown at clonal density in
attachment-independent conditions (spheroids). The attachment-
independent conditions exert even more strain on the cells, and
because spheroid formation was used extensively to enrich for stem
cells, the clonogenic spheroid formation assay probably identiﬁes the
population of cells that have the highest tumorigenic potential. We
speciﬁcally focused on common tumor-initiating cells markers such as
CD44 and CD133. CD44 is present at high levels in the majority of
DU145 cells, regardless of culture conditions (monolayer or spher-
oids). The CD133+ cells were also clearly identiﬁed in the spheroids,
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proliferate at the same rate as the CD44 cells within the spheroids
(data not shown). While these spheroids were grown in serum-
supplemented media (that usually promotes differentiation), the use
of serum-free deﬁned media also did not enrich the CD133+
population.
In summary, the study of prostate tumor-initiating cells is still an
evolving ﬁeld but the results to date suggest that a series of several
surface and/or metabolic markers may be needed to identify prostate
cancer-initiating cells.
4. Telomeres, telomerase and prostate cancer
Telomeres are nucleoprotein complexes that cap the ends of
human chromosomes [29]. As the cells divide, the telomeres shorten
by approximately 50–100 base pairs with each division [30]. In
addition, single-strand breaks of telomere DNA caused by oxidative
damage can lead to telomere attrition [31,32]. Telomeres present a
speciﬁc end-replication problem, recognized as early as 1970's [33,34],
and a specialized cellular enzyme, called telomerase is responsible for
telomere extension [35]. Telomerase is active in proliferating cells of
the skin, gastrointestinal system and blood [36–38]. While normal
prostate cells lack telomerase activity [39], telomerase is detected in
the majority of prostate cancer samples, being absent or present at
low levels in benign prostate hyperplasia (BPH) [40–45]. More
signiﬁcant is the fact that majority of the prostate cancer samples
have much shorter telomeres than the corresponding normal or BPH
prostate samples [39,46].
Prostate cancer cells have robust telomerase activity and several
commonly used prostate cancer cell lines show a signiﬁcant TRAP
signal (Fig. 1A). Similar to the results observed in primary tumor
samples (data not shown), these cell lines have relatively short
telomeres (Fig. 1B). The cell lines used were originally derived from
different metastatic sites and cultured in serum-supplementedmedia,
but primary prostate cancer cells cultured in our lab have shown the
same characteristics (high telomerase activity and short telomeres)Fig. 1. Prostate cancer cell lines have telomerase activity and short telomeres. (A) Telomere
Normal primary prostate epithelial cells are telomerase negative. The internal ampliﬁcati
(B) Terminal Restriction Fragment (TRF) assay on telomere DNA extracted from three d(data not shown). This is in contrast to normal prostate epithelial cells
which are telomerase (TRAP) negative (Fig. 1A).
Androgen ablation in a rat model leads to activation of telomerase
and further treatment with androgen reverses the effects and results
in the down-regulation of telomerase in these animals [47]. Similar
results were obtained in a primate model [48]. In sharp contrast,
telomerase regulation by androgens is reversed in prostate cancers.
Telomerase activity is up-regulated upon androgen stimulation and in
clinical specimens telomerase activity is signiﬁcantly reduced after
complete androgen ablation [49,50]. Recent studies have shown that
in prostate cancer cells the catalytic protein component of telomerase
(hTERT) promoter is the target of down-regulation by AR in
cooperation with p53 [51]. These experiments appear to reveal a
mechanism for the protective role of androgens in normal prostate
and suggest that prostate cancer cells might escape this mechanism by
mutations in the AR. There is general agreement that normal adult
prostate stem cells are AR+ but whether AR is expressed in tumor-
initiating cells is still a controversial topic. While some authors
support the idea that prostate tumor-initiating cells do not express AR
[52,53], recent evidence supports the notion that prostate tumor-
initiating cells are AR+ [24,54].
Chromosomal instability is an essential feature of prostate cancer,
being detected as early as prostatic intraepithelial neoplasia (PIN),
the earliest recognizable form of the disease. Using a high resolution,
quantitative in situ method of investigation for telomere length [55],
it was shown that the telomere length of high grade PINs were
considerably shorter than adjacent normal cells [56]. The telomere
shortening was restricted only to the luminal compartment,
suggesting that the basal cells may not be the source of neoplastic
transformation. This report supported previous studies showing that
a subset of PIN cells activate telomerase, become immortal and
eventually progress to fully invasive adenocarcinoma [41]. Combin-
ing this theory of neoplastic transformation with the evidence
provided by the presence of AR in prostate tumor-initiating cells
[24,54], we favor a model of prostate cancer in which telomere
shortening and telomerase activity play a central role (Fig. 2). UnderRepeat Ampliﬁcation Protocol (TRAP) on cell lysates from different prostate cell lines.
on standard used for quantifying telomerase activity levels is indicated by an arrow.
ifferent prostate cancer cell lines.
Fig. 2. Telomere dysfunction and telomerase activation play an important role in prostate malignant transformation.
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telomere shortening, a subset of transit amplifying cells of
intermediate phenotype will encounter severe chromosomal
instability. To escape from the blockade induced by critically
shortened telomeres, telomerase activation and subsequent cellular
immortalization, combined with other mutations, leads to the
development of prostate cancer. For example, cells in high grade
PIN lesions that have escaped replicative senescence have unlimited
proliferative capacity to accumulate additional mutations leading to
prostate cancer.
5. Telomerase activity in prostate tumor-initiating cells
Telomerase in normal stem cells is highly regulated and generally
expressed at low levels. The major function of the enzyme in the
normal stem cell compartment is believed to be the partial
maintenance of telomere homeostasis during self-renewal [57,58].
Importantly, all human adult stem cells (and normal somatic cells)
that have been examined progressively shorten their telomeres with
increased age. This telomere loss mechanism may have evolved as an
important anticancer mechanism by placing limitations on cells that
accumulated harmful mutations and preventing their clonal expan-
sion. This suggests that fully maintaining telomere length in normal
cells may increase the risk of developing cancer because cancer cellscannot enter replicative senescence and will ultimately achieve
indeﬁnite proliferation potential.
While there is no direct evidence about the levels of telomerase
activity in prostate stem cells, the expectancy is that these cells will
also have low levels of telomerase activity. The only experiments that
addressed the telomerase activity in isolated tumor-initiating cells of
solid tumors were performed in breast cancer, where the data
presented shows that breast tumor-initiating cells have telomerase
activity at similar levels with the main tumor mass cells, and
importantly, that these cells have relatively short telomeres [59].
Experiments performed in our lab show that putative prostate tumor-
initiating cells isolated from different cell lines have signiﬁcant
telomerase activity (Fig. 3). In the PC3 cell line, the surface markers
CD44 and CD133 were used to isolate populations of cells that exhibit
telomerase activity at the same level with the negative (low) fraction
and main population. Two cell lines (LNCaP and PC3) that differ in
terms of androgen response are shown for the CD133 marker,
suggesting that telomerase is universally expressed in tumor-initiat-
ing cells isolated from cancer cell lines containing putative cancer-
initiating markers. Experiments are under way to establish the
presence of telomerase in tumor-initiating cells isolated from primary
prostate tumor samples, as well as from distant metastatic sites in
patients with advanced disease. We expect that prostate tumor-
initiating cells isolated from these sources will have active telomerase,
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tumor-initiating cells (Marian et al., unpublished data).
6. Circulating prostate tumor-initiating cells
Metastasis is the major cause of death in patients with advanced
prostate cancer, the most frequent site for metastatic lesions being the
bone [60]. There are still many unanswered questions about the
metastatic process, but for the purpose of this review we are
interested in how the tumor-initiating cells and circulating tumor
cells (CTC) ﬁt in the general scheme of cancer progression. It was
already hypothesized that a subset of tumor-initiating cells are
responsible for distant metastasis [61,62]. Support for this hypothesis
comes from the inherent properties of tumor-initiating cells. Only
cells that have high plasticity and the capacity to form tumors will be
responsible for the formation of metastatic lesions. These cells need to
adapt to a new speciﬁc niche and the heterogeneous nature of tumor-
initiating cells make them ideal candidates for this task. Detection of
CTCs has improved with the advent of automated systems, some of
which are approved for clinical use. One of these systems can be used
as a survival predictor in patients with prostatemetastatic cancer [63].
Very signiﬁcant from the perspective of this review is the discovery
that CTCs in the patients with advanced prostate cancer have
signiﬁcant levels of telomerase activity [64]. In the same study,
telomerase activity was also detected in 23% of patient CTC specimens,
all of which had undetectable serum PSA levels. This suggests the
potential applications of this technique, not only for early diagnostic,
but also for treatment monitoring. If circulating tumor cells contain
small populations of tumor-initiating cells, it becomes important to
determine if these cells are telomerase positive. If telomerase activity
is maintained in tumor-initiating cells after dissemination, these cells
will most likely have signiﬁcant levels of telomerase activity. If these
cells are telomerase negative, the up-regulation of telomerase activity
will most likely occur after the initial period of quiescence commonly
associated with disseminated cancer cells. Nevertheless, without
telomere maintenance by telomerase, metastatic lesions cannot
proliferate to a signiﬁcant level that makes them dangerous for the
patient. The presence of telomerase in prostate CTCs can also serve asFig. 3. Putative prostate tumor-initiating cells have telomerase activity which can be inhibi
were isolated by ﬂow cytometry using surface markers (CD44 and CD133) and equal cell lys
telomerase inhibitor drug (2 μM) before sorting. HeLa cells were used as positive controls.a direct monitoring tool for telomerase inhibition therapy. The access
to blood samples ismore feasible and less invasive than the alternative
bone marrow biopsies.
7. Telomerase as a therapeutic target for prostate cancer
Telomerase is also an attractive target for cancer therapy. The
enzyme is present in majority of cancer cells analyzed but absent in
almost all normal somatic cells, making telomerase inhibitors highly
speciﬁc and telomerase a universal oncology target. Moreover,
because normal cells have longer telomeres compared to cancer
cells, the toxicity of these inhibitors in normal tissues is minimal.
Several strategies have been employed for targeting telomerase, and
several reviews have been written on the subject in recent years
[65,66]. Despite a multitude of pre-clinical studies, only two of these
strategies have led to drugs that are currently in clinical trials. The ﬁrst
strategy targets the functional RNA (hTR or hTERC) component of the
telomerase enzyme with N3′–P5′ thio-phosphoramidate oligonucleo-
tides [67]. The 13-mer compound used in these studies, GRN163L, is
an antagonist that has high afﬁnity to the hTR sequence and acts as an
enzymes inhibitor (not as an antisense approach targeting mRNA).
Once GRN163L is bound to the hTR component, it blocks access of
hTERT (the catalytic protein component of telomerase) and prevents
the assembly of an active telomerase enzyme. This leads to telomerase
inhibition and progressive telomere shortening, eventually leading to
telomere uncapping and cell death. GRN163L is currently in Phase I
and I/II clinical trials in several hematological and solid tumor
malignancies. While not tested speciﬁcally for prostate cancer in
clinical trials, this telomerase antagonist along with its un-lipidated
precursor (GRN163) was shown to be effective in prostate xenograft
models, and thus may become an effective therapy for prostate cancer
[68–70].
A second strategy employs active telomerase immunotherapy
directed towards the hTERT catalytic component. The presence of
telomerase-speciﬁc cytotoxic T lymphocytes has been discovered in
some patients, suggesting that the immune system can elicit a
response to telomerase-presenting cells even in the absence of
vaccination [71]. In a clinical trial initiated in patients with prostateted by telomerase inhibitors (GRN163L). Different populations of tumor-initiating cells
ate amounts were used for the TRAP assay. The cells were pre-treated for 72 h with the
The internal ampliﬁcation standard is indicated by an arrow.
Fig. 4. Telomerase inhibitors used in combination with standard therapies can target tumor-initiating cells. Tumor-initiating cells escape conventional therapies and are responsible
for relapse but telomerase inhibition can target all the tumor cell fractions and lead to a durable response.
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transfected with an mRNA encoding a chimeric lysosome-associated
membrane protein-1 (LAMP) hTERT protein which allows a con-
comitant CD8+ and CD4+ Tcell response. For the patients involved in
this study, the vaccine had a signiﬁcant impact on PSA levels and also
led to a transient elimination of the PSA-expressing circulating tumor
cells [72]. Another clinical study with prostate cancer patients
revealed a signiﬁcant induction of hTERT-speciﬁc T lymphocytes in
response to inoculations with dendritic cells pulsed with a HLA-A2-
restricted hTERT I540 peptide and keyhole limpet hemocyanin (KLH)
[73]. Both these studies, along with clinical trials initiated for other
malignancies [74] have shown minimal side-effects and no adverse
effects on normal bone marrow stem cells. These cancer vaccination
studies appear very promising, and some of the telomerase vaccines
are moving forward to Phase II and III clinical trials.
8. Telomerase inhibition in prostate tumor-initiating cells
Previous reports have shown that GRN163L inhibits telomerase
activity and eliminates the clonogenic potential of tumor-initiating
cells from several multiple myeloma (MM) cell lines. The same results
were observed when using primary clinical samples, where tumor-
initiating cells isolated from the bone marrow of patients with MM
were exposed to GRN163L [75]. In our labwe established the presence
of active telomerase in putative prostate tumor-initiating cells isolated
from prostate cell lines andwe proceeded to show that the telomerase
inhibitor GRN163L is able to inhibit the enzymatic activity in these cells
with the same efﬁciency as in themain population (Fig. 3). Telomerase
inhibition induced progressive telomere shortening in tumor-initiat-
ing cells at the same rate found in the cell line from which they were
derived (data not shown). After the telomeres become critically short,
the cells will enter apoptosis and die (data not shown). These
experiments suggest that GRN163L may be a valuable therapy for the
treatment of prostate cancer, its unique mode of action being able to
target the elusive putative tumor-initiating cells that are usually
resistant to conventional therapies.
Assuming the same telomere shortening dynamics are maintained
in vivo, we propose a therapy regimen that combines conventional
approaches (surgery and chemotherapy/radiotherapy) with telomer-
ase inhibitors (Fig. 4). While the standard therapy will have a de-bulking effect relatively fast, sustained telomerase inhibition will lead
to critical telomere attrition and ultimately cell death in the small
populations of cells that survive the ﬁrst therapeutic intervention,
including the tumor-initiating cells. The effect of this drug on normal
stem cells in the organism should be minimal due to their slower
proliferation rates, lower telomerase activity, and longer telomeres.
This should provide an ample therapeutic window in which the
shorter telomere-bearing tumor cells will be eliminated. After the
telomerase inhibitor drug is removed, telomerase activity will return
to normal levels in the proliferating cells.
Direct telomerase inhibitors are not the only agents that can be
used with this therapy strategy, and vaccines targeting telomerase
positive cells should be equally efﬁcient, unless tumor-initiating cells
have special mechanisms to escape detection by the immune system.
Preliminary experiments from clinical trials show that the vaccine
might target and eliminate the cancer cells found in circulation [73],
but based on the available data there is no direct evidence that the
vaccines are targeting speciﬁcally tumor-initiating cells. This brings up
a very important issue related to the availability of biomarkers to
monitor telomerase inhibition therapy in prostate cancer. Because
telomerase inhibitors will act promiscuously on all the cells in the
organism, several cell types are available to assess therapy efﬁciency.
The less invasive approach makes use of peripheral mononuclear
blood cells (PBMCs). Activated leukocytes have low but detectable
telomerase activity, therefore telomerase inhibition in this compart-
ment can be used in various pharmacodynamic studies [76]. A more
direct approach is to measure telomerase activity in CTCs or in
disseminated cancer cells isolated from bone marrow aspirates.
9. Concluding remarks
The origin and identiﬁcation of tumor-initiating cells is an exciting
area of research, full of possibilities but also controversies that
generate vivid arguments. The majority of these arguments are
generated by the theoretical concepts associated with the “cancer
stem cell” hypothesis and by some technical issues that make the
isolation and characterization of these cells problematic [77,78]. Some
of these concerns are valid and more investigations are required to
address these issues. However, the most valuable application of this
scientiﬁc knowledge should be the discovery of new therapeutic
295C.O. Marian, J.W. Shay / Biochimica et Biophysica Acta 1792 (2009) 289–296strategies for the treatment of cancer. Telomerase inhibition might be
one of these novel targeted therapies, and due to the fundamental role
of telomerase in most malignancies, we propose that telomerase
therapeutics may also target tumor-initiating cells. If the source of
tumor initiation is eradicated by targeting the ability of cell to
maintain the end of the chromosomes, the quest for a cure might also
come to an end.
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